The shadow of generic challenges has consistently loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of connected medicinal ventures. While initial periods saw impressive gains, the patent expiration has created the way for cheaper alternatives, likely diminishing profitability and presenting a significa